Sector News

Drug spending growth slowed last year—but still hit $323B

May 4, 2017
Life sciences

Despite what you may have heard about drug pricing and expenses getting out of hand, net spending growth actually fell in the U.S. last year. After discounts, pharmaceutical spending increased 4.8% in 2016, down from 8.9% growth recorded in 2015.

The figures are courtesy of the QuintilesIMS Institute, which released its annual drug spending report on Thursday. All told, net U.S. drug expenses reached $323 billion last year, while invoice-level spending was $450 billion.

Taken together, the figures represent an industrywide rebate and discounting level of 28%. Spending growth also slowed on an invoice basis in 2016, to 5.8%, from about 12.5% in 2015 and about 15% in 2014.

Importantly, the numbers represent overall growth, and drug spending in the U.S. continued to expand in 2016. Last year’s net spending increase followed an 8.9% jump in 2015, and an even higher leap of about 10% for 2014.

Other big industry trends, according to QuintilesIMS, include a continued shift to specialty medicine spending, a deceleration of invoice price hikes, and a downturn in new drug sales. On specialty meds, the experts noted that the class now accounts for $384 of the $895 per person per year spent on pharmaceuticals in the U.S.

For invoice price hikes in recent history, QuintilesIMS’ report notes a high point back in 2014, when average invoice price increases were 13.7% for the year. That number fell to 12% in 2015 and 9.2% last year as the industry continued to grapple with broad pricing pressures. Average price increases after discounts were even lower at 4.5% for 2014, 2.5% for 2015 and 3.5% for last year.

New drugs—those on the market for less than 24 months—generated $13.9 billion in sales last year, a downturn from $17.3 billion in 2015 and $20.6 billion in 2014. As the analysts note, the FDA approved fewer than half the number of new meds last year as it did in 2014 and 2015.

So far this year, however, that trend seems to be reversing. The FDA approved more new meds during the first quarter of 2017 than during the same period of any year in recent history. The agency didn’t stop there, and has since brought its total new drug approval tally to 19 for this year.

Looking ahead, QuintilesIMS experts aren’t expecting huge price increases in the coming years. Report authors write that “drug manufacturer responses to heightened market competition and scrutiny of drug pricing are expected to result in more modest levels of invoice (and net) price growth in the forecast period.”

QuintilesIMS releases its industry analysis as politicians in Washington work to take on drug costs through a variety of proposals, including drug importation and Medicare price negotiation. Their efforts are boosted by broad public support, with a Kaiser Family Foundation poll this week finding that 60% of Americans consider the issue a “top priority” for President Donald Trump and Congress.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.